NEXT-GENERATION sequencing use rose in advanced cancer, but access remained uneven across socioeconomic, racial, and ...
"In our study, we showed that fine needle aspiration (FNA) biopsy material can be a good source for next-generation sequencing (NGS) for patients with metastatic prostate cancer. Based on these ...
New data show precision cancer testing still lags for Black, Hispanic, low-income and Medicare/Medicaid patients, delaying ...
Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.
Advances in next-generation sequencing (NGS) and synthetic DNA technologies are reshaping oncology research by enabling earlier cancer detection, more accurate biomarker discovery, and sensitive ...
A study led by researchers at a community hospital in Sapporo, Japan found that comprehensive genomic testing using a ...
The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...
Unlock the latest liquid biopsy market data. Explore growth drivers, precision oncology shifts, and the tech fueling ...
Tissue Cryopreservation Preserves More Future Options The way a patient's tumor tissue is preserved after surgery is ...
This review examines how next-generation protein sequencing and analysis technologies are expanding proteomics beyond the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results